Rare Disease Treatment Progress

Egetis Therapeutics highlights rare disease treatment progress at upcoming investor conferences.

Egetis Therapeutics (NASDAQ Stockholm: EGTX) has announced that it will participate in upcoming investor conferences in September. The company's lead drug candidate, Emcitate® (tiratricol), is being developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. The European Commission approved Emcitated® as the first and only treatment for MCT8 deficiency in EU in February 2025. The U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for Emcitates (tirsatricolic) for the use of MCT 8 deficiency. The application has been granted Priority Review and assigned a target action date of September 28, 2026.